Siemens Completes Acquisition of Dade Behring
November 06 2007 - 12:04PM
PR Newswire (US)
Complementing business of Siemens Medical Solutions Diagnostics
ERLANGEN, Germany, Nov. 6 /PRNewswire-FirstCall/ -- Siemens has
successfully completed the acquisition of Dade Behring Holdings,
Inc. The laboratory diagnostics company joins the existing business
of Siemens Medical Solutions Diagnostics. As the market leader in
the attractive and rapidly growing field of in vitro diagnostics,
Siemens now can offer its customers a unique and comprehensive
healthcare solutions' portfolio, which brings together the entire
medical imaging, laboratory diagnostics and clinical information
technology (IT) value chain under one roof. (Logo:
http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ) "The
acquisition of Dade Behring, which holds a strong position in
clinical chemistry, ideally complements our acquisitions of
Diagnostic Products Corporation and Bayer Diagnostics," explained
Erich R. Reinhardt, member of the Managing Board of Siemens AG and
President and CEO of Siemens Medical Solutions. "The implementation
of integrated IT and clinical solutions from Siemens will help
improve workflow efficiency throughout the healthcare enterprise,
from admissions and administration, to the laboratory and the
radiology department. This will enable our customers to increase
the quality of patient care while simultaneously reducing costs,"
Reinhardt added. As the first and only global fully integrated
diagnostics company, Siemens Medical Solutions is in a unique
position to leverage trendsetting solutions across the entire
healthcare continuum - from prevention to diagnosis, to therapy and
care. Siemens (Berlin and Munich) is a global powerhouse in
electrical engineering and electronics. The company has around
475,000 employees (incl. discontinued operations) working to
develop and manufacture products, design and install complex
systems and projects, and tailor a wide range of services for
individual requirements. Siemens provides innovative technologies
and comprehensive know-how to benefit customers in over 190
countries. Founded more than 160 years ago, the company focuses on
the areas of Information and Communications, Automation and
Control, Power, Transportation, Medical, and Lighting. In fiscal
2006 (ended September 30), Siemens had sales of euro 87.3 billion
and net income of euro 3.033 billion, according to U.S. GAAP.
Further information is available on the Internet at:
http://www.siemens.com/ Siemens Medical Solutions of Siemens AG is
one of the world's largest suppliers to the healthcare industry.
The company is known for bringing together innovative medical
technologies, healthcare information systems, management
consulting, and support services, to help customers achieve
tangible, sustainable, clinical and financial outcomes.
Acquisitions in the area of in-vitro diagnostics - such as
Diagnostic Products Corporation Bayer Diagnostics and Dade Behring-
mark a significant milestone for Siemens as it becomes the first
full service diagnostics company. Employing more than 41,000 people
worldwide and operating in over 130 countries, Siemens Medical
Solutions reported sales of euro 8.23 billion, orders of euro 9.33
billion and group profit of euro 1.06 billion for fiscal 2006
(Sept. 30), according to U.S. GAAP. Further information can be
found by visiting http://www.siemens.com/medical. This document
contains forward-looking statements and information - that is,
statements related to future, not past, events. These statements
may be identified by words as "expects," "looks forward to,"
"anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "will" or words of similar meaning. Such statements
are based on our current expectations and certain assumptions, and
are, therefore, subject to certain risks and uncertainties. A
variety of factors, many of which are beyond Siemens' control,
affect its operations, performance, business strategy and results
and could cause the actual results, performance or achievements of
Siemens worldwide to be materially different from any future
results, performance or achievements that may be expressed or
implied by such forward-looking statements. For us, particular
uncertainties arise, among others, from: changes in general
economic and business conditions (including margin developments in
major business areas); the challenges of integrating major
acquisitions and implementing joint ventures and other significant
portfolio measures; changes in currency exchange rates and interest
rates; introduction of competing products or technologies by other
companies; lack of acceptance of new products or services by
customers targeted by Siemens worldwide; changes in business
strategy; the outcome of pending investigations and legal
proceedings; our analysis of the potential impact of such matters
on our financial statements; as well as various other factors. More
detailed information about our risk factors is contained in
Siemens' filings with the SEC, which are available on the Siemens
website, http://www.siemens.com/, and on the SEC's website,
http://www.sec.gov/. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described
in the relevant forward-looking statement as expected, anticipated,
intended, planned, believed, sought, estimated or projected.
Siemens does not intend or assume any obligation to update or
revise these forward-looking statements in light of developments
which differ from those anticipated.
http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGODATASOURCE:
Siemens Medical Solutions CONTACT: Frank Sarfeld, +49 160 9019
0499, Web site: http://www.siemens.com/medical
http://www.siemens.com/
Copyright